ArticleScientific reports2026
Serum Aβ42 and hemoglobin as independent predictors of post-stroke cognitive impairment: a comparative biomarker study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stroke is a devastating medical condition, and one of its side effects is post-stroke cognitive impairment (PSCI). The objective of this study is to investigate and analyse the potential indicators for post-stroke cognitive decline (PSCI), with a particular emphasis on the biomarkers Aβ42 (beta-amyloid 42) and haemoglobin (Hb) levels. Based on clinical diagnosis, 120 participants were divided into three groups: PSCI (n = 40), PSCN (n = 40), and AD (n = 40): Alzheimer's disease (AD), post-stroke cognitive impairment (PSCI), and post-stroke cognitively normal (PSCN). The first data set was documented. The study examined the relationship between Aβ42 and Hb and cognitive score. Finally, ROC curve and logistic regression analysis were used to analyze the aforementioned indicators' PSCI prediction abilities. Compared to the AD group (104.00 ± 64.43 pg/ml, 112.4 ± 19.05 g/L) and the PSCN group (87.38 ± 66.69 pg/ml, 134.8 ± 13.28 g/L), the PSCI group had lower levels of Aβ42 (69.20 ± 49.36 pg/ml) and Hb (110.53 ± 22.73 g/L) (P < 0.05). The study identified Hb, age, and hypertension as the main risk factors for PSCI, while Aβ42 was noted as a pertinent risk factor. The sensitivity level was 0.800, specificity was 0.625, and area under the curve for the combination diagnosis of Aβ42 and Hb was 0.7169, according to the ROC curve. The risk variables for PSCI, Aβ42 and Hb, are considerably lower in the blood of patients with PSCI compared to controls. The performance of differential diagnosis will be enhanced when the two are integrated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.